DiaMedica Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . DiaMedica Therapeutics
DMAC Stock  USD 8.17  0.23  2.74%   
DiaMedica Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing DiaMedica Therapeutics' valuation are provided below:
Market Capitalization
437.5 M
Earnings Share
(0.71)
We have found one hundred twenty available fundamental signals for DiaMedica Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of DiaMedica Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 4, 2026, Market Cap is expected to decline to about 132.5 M. In addition to that, Enterprise Value is expected to decline to about 128.8 M

DiaMedica Therapeutics Total Revenue

500,000

Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.3 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 5.09. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with DiaMedica Stock
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

DiaMedica Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets56 M53.3 M21.3 M
Slightly volatile
Short and Long Term Debt Total285.8 K391 K346.7 K
Slightly volatile
Other Current Liabilities5.2 M5 M1.5 M
Slightly volatile
Total Current Liabilities6.5 M6.2 M2.3 M
Slightly volatile
Property Plant And Equipment Net515.6 K491.1 K189.2 K
Slightly volatile
Accounts Payable580 K1.1 M661.1 K
Slightly volatile
Cash3.5 M3.5 M3.7 M
Slightly volatile
Non Current Assets Total1.6 M1.6 M744.7 K
Very volatile
Cash And Short Term Investments53.3 M50.8 M20.2 M
Slightly volatile
Net Receivables176.2 K271.4 K195.8 K
Slightly volatile
Common Stock Shares Outstanding48.8 M46.5 M17.8 M
Slightly volatile
Liabilities And Stockholders Equity56 M53.3 M21.3 M
Slightly volatile
Other Stockholder Equity218.2 M207.8 M79.8 M
Slightly volatile
Total Liabilities6.8 M6.5 M2.4 M
Slightly volatile
Property Plant And Equipment Gross653.3 K622.1 K221.6 K
Slightly volatile
Total Current Assets53.9 M51.3 M20.5 M
Slightly volatile
Property Plant Equipment676.2 K644 K213.5 K
Slightly volatile
Capital Surpluse114.6 M109.2 M52.7 M
Slightly volatile
Net Invested Capital30.1 M46.8 M17.7 M
Slightly volatile
Net Working Capital29.7 M45.1 M17.3 M
Slightly volatile

DiaMedica Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization33.3 K35.1 K355.3 K
Slightly volatile
Other Operating Expenses32.2 M30.7 M12.2 M
Slightly volatile
Research Development23 M21.9 M8 M
Slightly volatile
Total Operating Expenses32.2 M30.7 M12.2 M
Slightly volatile
Selling General Administrative9 M8.5 M3.9 M
Slightly volatile
Interest Income47.1 K44.9 K22.7 K
Slightly volatile
Reconciled Depreciation24.3 K44.9 K16.1 K
Slightly volatile
Selling And Marketing Expenses180.4 K221.9 K125.3 K
Slightly volatile

DiaMedica Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.3 M5.2 M3.8 M
Slightly volatile
Depreciation33.3 K35.1 K355.3 K
Slightly volatile
Capital Expenditures21.4 K22.5 K43.6 K
Slightly volatile
End Period Cash Flow3.5 M3.5 M3.7 M
Slightly volatile
Stock Based Compensation2.5 M2.4 M1.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio49.2451.832 K
Slightly volatile
Days Sales Outstanding343424446
Pretty Stable
Invested Capital2.5 M2.6 M2.9 M
Slightly volatile
Average Payables600.3 K571.7 K562.9 K
Slightly volatile
Stock Based Compensation To Revenue0.991.121.2182
Slightly volatile
Capex To Depreciation0.70.743.0394
Slightly volatile
EV To Sales12.5313.192 K
Slightly volatile
Inventory Turnover2.9 K3.2 K3.5 K
Slightly volatile
Days Of Inventory On Hand0.080.09140.0997
Slightly volatile
Payables Turnover0.00620.0070.0073
Slightly volatile
Sales General And Administrative To Revenue4.384.935.3812
Slightly volatile
Research And Ddevelopement To Revenue11.9210.49.563
Very volatile
Capex To Revenue0.110.120.2755
Slightly volatile
Cash Per Share0.940.980.9659
Slightly volatile
Days Payables Outstanding52.5 K53.8 K50.2 K
Slightly volatile
Income Quality1.051.040.839
Slightly volatile
Intangibles To Total Assets0.10.110.1781
Slightly volatile
Current Ratio6.447.458.0461
Slightly volatile
Receivables Turnover1.20.890.8601
Pretty Stable
Capex Per Share7.0E-47.0E-40.0087
Slightly volatile
Average Receivables51.7 K29 K30 K
Pretty Stable
Revenue Per Share0.05190.05810.0597
Slightly volatile
Interest Debt Per Share0.00920.00970.0318
Pretty Stable
Debt To Assets0.0080.00840.9148
Slightly volatile
Operating Cycle393542317
Slightly volatile
Days Of Payables Outstanding52.5 K53.8 K50.2 K
Slightly volatile
Ebt Per Ebit1.081.050.969
Very volatile
Quick Ratio6.447.458.0461
Slightly volatile
Net Income Per E B T1.121.151.0287
Pretty Stable
Cash Ratio0.610.652.5353
Pretty Stable
Days Of Inventory Outstanding0.080.09140.0997
Slightly volatile
Days Of Sales Outstanding343424446
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.191.151.0874
Slightly volatile
Fixed Asset Turnover4.924.694.9565
Slightly volatile
Debt Ratio0.0080.00840.9148
Slightly volatile
Price Sales Ratio49.2451.832 K
Slightly volatile
Asset Turnover0.02980.03140.0353
Slightly volatile

DiaMedica Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap132.5 M252.3 M150.1 M
Pretty Stable
Enterprise Value128.8 M249.2 M146.5 M
Pretty Stable

DiaMedica Fundamental Market Drivers

DiaMedica Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About DiaMedica Therapeutics Financial Statements

DiaMedica Therapeutics stakeholders use historical fundamental indicators, such as DiaMedica Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DiaMedica Therapeutics' assets and liabilities are reflected in the revenues and expenses on DiaMedica Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.2 K9.7 K
Cost Of Revenue44.9 K47.1 K
Stock Based Compensation To Revenue 1.12  0.99 
Sales General And Administrative To Revenue 4.93  4.38 
Research And Ddevelopement To Revenue 10.40  11.92 
Capex To Revenue 0.12  0.11 
Revenue Per Share 0.06  0.05 
Ebit Per Revenue(12.17)(12.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
How To Invest In DiaMedica
Details
Is DiaMedica Stock a good investment?
Details
What is DiaMedica Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.71)
Return On Assets
(0.38)
Return On Equity
(0.64)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY